Spotlight On... Bavarian Nordic launches MRSA vaccine effort with partner Evaxion; Merck's Gardasil vaccines grow to $1.9B in 2015 sales; Whooping cough booster protection fades, study says; and more...

Bavarian Nordic has agreed to partner with Evaxion Biotech to develop a vaccine against methicillin-resistant Staphylococcus aureus (MRSA). The pair will set out to create a vaccine based on Bavarian Nordic's MVA-BN vaccine platform and will utilize Evaxion's computer-based tech to discover novel antigens. According to a release, Evaxion has demonstrated "promising" preclinical results, and the MVA-BN-based candidate will be tested in further preclinical models; human testing could begin in 2019. The Technical University of Denmark will assist in the preclinical testing. More from FierceBiotechIT

> Merck's ($MRK) Gardasil and Gardasil 9 franchise brought in $1.9 billion in 2015, the drugmaker reported, a 10% increase from 2014. Release

> A study of 175,000 children in California shows that whooping cough booster protection begins to fade rapidly after one year. Report

> With 250 confirmed dengue cases since Oct. 29, 2015, the mayor of Hawaii's Big Island has declared a state of emergency. Report

> The Institut Pasteur Foundation in Dakar is establishing a plant to produce yellow fever vaccines for local use. Report

> A new offer to take Sinovac Biotech ($SVA) private has valued the Chinese vaccines company at $390 million, FiercePharmaAsia reported. News

> According to a new study, every dollar spent expanding vaccine use could lead to $44 in savings. Release

> Transgene's TG4010 vaccine plus chemo improved progression-free survival in advanced NSCLC patients compared to placebo plus chemotherapy. News

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.